Estimated dopamine D2 receptor occupancy and remission in schizophrenia: Analysis of the catie data

Journal of Clinical Psychopharmacology

Volumn 33, Issue 5, 2013, Pages 682-685

  Moriguchi, Sho ^a   Bies, Robert R ^a   Remington, Gary ^a   Suzuki, Takefumi ^a   Mamo, David C ^a   Watanabe, Koichiro ^a   Mimura, Masaru ^a   Pollock, Bruce G ^a   Uchida, Hiroyuki ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; OLANZAPINE; PALIPERIDONE; RISPERIDONE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; DRD2 PROTEIN, HUMAN; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; PROTEIN BINDING;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR OCCUPANCY; REMISSION; SCHIZOPHRENIA; BLOOD; BRAIN; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NONLINEAR SYSTEM; PROTEIN BINDING; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME; UNITED STATES; CLINICAL TRIAL; DRUG EFFECTS;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NONLINEAR DYNAMICS; PIPERAZINES; PROTEIN BINDING; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, DOPAMINE D2; REMISSION INDUCTION; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; DOPAMINE D2 RECEPTOR ANTAGONISTS;

EID: 84883817566     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182979a0a     Document Type: Article

References (26)

1. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161:1-56
2. Uchida H, Suzuki T, Takeuchi H, et al. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: Meta-Analysis. Schizophr Bull. 2011;37:788-799
3. Farde L, Nyberg S, Oxenstierna G, et al. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-Treated schizophrenic patients. J Clin Psychopharmacol. 1995;15:19SY23S
4. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157: 514-520
5. Uchida H, Takeuchi H, Graff-Guerrero A, et al. Dopamine d2 receptor occupancy and clinical effects: A systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31:497-502
6. Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538-544
7. Sakurai H, Bies RR, Stroup ST, et al. Dopamine D2 receptor occupancy and cognition in schizophrenia: Analysis of the CATIE data. Schizophr Bull. 2013;39:564-574
8. Nyberg S, Farde L, Halldin C, et al. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry. 1995;152:173-178
9. Suzuki T, Uchida H, Watanabe K, et al. Treatment target in schizophrenia: A critical review and a clinical suggestion. Psychopharmacol Bull. 2008;41:80-102
10. Remington G, Seeman P, Feingold A, et al. Extended antipsychotic dosing in the maintenance treatment of schizophrenia: A double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72:1042-1048
11. Uchida H, Takeuchi H, Graff-Guerrero A, et al. Predicting dopamine D receptor occupancy from plasma levels of antipsychotic drugs: A systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31:318-325
12. Uchida H, Pollock BG, Bies RR, et al. Predicting age-specific dosing of antipsychotics. Clin Pharmacol Ther. 2009;86:360-362
13. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophr Bull. 2003;29:15-31
14. Feng Y, Pollock BG, Coley K, et al. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol. 2008;66:629-639
15. Wessels AM, Bies RR, Pollock BG, et al. Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. J Clin Pharmacol. 2011;51:1587-1591
16. Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008;48:157-165
17. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: Proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441-449
18. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276
19. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm. 1977;5:445-479
20. Cha TA, Beall E, Irvine B, et al. At least five related, but distinct, hepatitis C viral genotypes exist. Proc Natl Acad Sci U S A. 1992;89:7144-7148
21. Uchida H, Mamo DC, Pollock BG, et al. Predicting plasma concentration of risperidone associated with dosage change: A population pharmacokinetic study. Ther Drug Monit. 2012; 34:182-187
22. Uchida H, Bies RR, Suzuki T, et al. Predicting dopamine D2 receptor occupancy following antipsychotic dose reduction: A pilot PET study. Eur Arch Clin Neurosci. 2011;261:S65
23. Mizuno Y, Bies RR, Remington G, et al. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: A cross-sectional study. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37:182-187
24. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225-235
25. Turrone P, Remington G, Kapur S, et al. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biol Psychiatry. 2005;57:406-411
26. Bedard AM, Maheux J, Levesque D, et al. Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues. Neuropsychopharmacology. 2011;36:1248-1259